Suppr超能文献

接受过克拉屈滨片治疗患者的长期疗效:意大利多发性硬化症登记处(CLARINET-MS)的真实世界分析

Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS).

作者信息

Patti Francesco, Visconti Andrea, Capacchione Antonio, Roy Sanjeev, Trojano Maria

机构信息

Azienda Ospedaliera-Universitaria, "Policlinico Vittorio Emanuele", Catania via Santa Sofia 78, Catania, 95123, Italy.

Merck Serono S.p.A., Rome, Italy, an affiliate of Merck KGaA, Darmstadt, Germany.

出版信息

Ther Adv Neurol Disord. 2020 Jun 10;13:1756286420922685. doi: 10.1177/1756286420922685. eCollection 2020.

Abstract

BACKGROUND

The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with multiple sclerosis (MS) in Italy, using data from the Italian MS Registry.

METHODS

Real-world data (RWD) from Italian MS patients who participated in cladribine tablets randomised clinical trials (RCTs; CLARITY, CLARITY Extension, ONWARD or ORACLE-MS) across 17 MS centres were obtained from the Italian MS Registry. RWD were collected during a set observation period, spanning from the last dose of cladribine tablets during the RCT (defined as baseline) to the last visit date in the registry, treatment switch to other disease-modifying drugs, date of last Expanded Disability Status Scale recording or date of the last relapse (whichever occurred last). Time-to-event analysis was completed using the Kaplan-Meier (KM) method. Median duration and associated 95% confidence intervals (CI) were estimated from the model.

RESULTS

Time span under observation in the Italian MS Registry was 1-137 (median 80.3) months. In the total Italian patient population ( = 80), the KM estimates for the probability of being relapse-free at 12, 36 and 60 months after the last dose of cladribine tablets were 84.8%, 66.2% and 57.2%, respectively. The corresponding probability of being progression-free at 60 months after the last dose was 63.7%. The KM estimate for the probability of not initiating another disease-modifying treatment at 60 months after the last dose of cladribine tablets was 28.1%, and the median time-to-treatment change was 32.1 (95% CI 15.5-39.5) months.

CONCLUSION

CLARINET-MS provides an indirect measure of the long-term effectiveness of cladribine tablets. Over half of MS patients analysed did not relapse or experience disability progression during 60 months of follow-up from the last dose, suggesting that cladribine tablets remain effective in years 3 and 4 after short courses at the beginning of years 1 and 2.

摘要

背景

CLARINET-MS研究通过利用意大利多发性硬化症(MS)登记处的数据,对意大利的MS患者进行随访,评估了克拉屈滨片的长期疗效。

方法

从意大利MS登记处获取了来自17个MS中心参与克拉屈滨片随机临床试验(RCT;CLARITY、CLARITY扩展、ONWARD或ORACLE-MS)的意大利MS患者的真实世界数据(RWD)。RWD是在设定的观察期内收集的,从RCT期间克拉屈滨片的最后一剂(定义为基线)到登记处的最后就诊日期、转用其他疾病修饰药物、最后一次扩展残疾状态量表记录日期或最后一次复发日期(以最后发生者为准)。使用Kaplan-Meier(KM)方法完成事件发生时间分析。从模型中估计中位持续时间和相关的95%置信区间(CI)。

结果

意大利MS登记处的观察时间跨度为1至137个月(中位值80.3个月)。在意大利患者总数(n = 80)中,最后一剂克拉屈滨片后12、36和60个月无复发概率的KM估计值分别为84.8%、66.2%和57.2%。最后一剂后第60个月无疾病进展的相应概率为63.7%。最后一剂克拉屈滨片后60个月未开始另一种疾病修饰治疗概率的KM估计值为28.1%,治疗改变的中位时间为32.1(95%CI 15.5 - 39.5)个月。

结论

CLARINET-MS提供了克拉屈滨片长期疗效的间接测量。超过一半的分析MS患者在最后一剂后的60个月随访期间未复发或出现残疾进展,这表明克拉屈滨片在第1年和第2年初短期用药后的第3年和第4年仍然有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4fa/7294475/b04f8af844c9/10.1177_1756286420922685-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验